|
|
|
|
|
The ASCO Post
FDA Approves First-Line Ramucirumab Plus Erlotinib for Metastatic EGFR-Mutated NSCLC - The ASCO Post
|
|
|
|
On May 29, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza, injection, 10 mg/mL solution) in combination with erlotinib for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
Ramucirumab plus erlotinib is the first and only FDA-approved anti–vascular endothelial growth factor (VEGF) receptor/EGFR tyrosine kinase inhibitor combination therapy for metastatic EGFR-mutated NSCLC.
This approval is based on efficacy and safety data from the global, randomized, placebo-controlled phase III RELAY trial.
Read more
|
|
|
|
|
|
|
|
|
Targeted Oncology
FDA Approves Frontline Ramucirumab/Erlotinib for EGFR+ mNSCLC
|
|
|
|
The FDA has approved ramucirumab (Cyramza) in combination with erlotinib (Tarceva) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations, according to a press release from Eli Lilly.1
This marks the only anti–VEGFR/EGFR tyrosine kinase inhibitor combination regimen approved by the FDA for the treatment of patients with EGFR-mutant metastatic NSCLC.
"The approval of this new first-line metastatic EGFR-mutated non–small cell lung cancer regimen, which inhibits the VEGFR and EGFR pathways together, is an important milestone in the treatment of this disease.
Read more
|
|
|
|
|
|
|
|
|
MedWireNews
Adjuvant osimertinib ‘practice changing’ for early-stage EGFR-mutated NSCLC
|
|
|
|
medwireNews: Patients with stage IB–IIIA non-small-cell lung cancer (NSCLC) harboring EGFR mutations derive a significant disease-free survival (DFS) benefit from adjuvant treatment with osimertinib, shows the phase 3 ADAURA trial. The third-generation EGFR–tyrosine kinase inhibitor was associated with a significant 79% reduction in the risk for relapse or death relative to placebo in these patients, reported Roy Herbst, from the Yale School of Medicine in New Haven, Connecticut, USA, at the virtual 2020 ASCO Annual Meeting.
Read more
|
|
|
|
|
|
|
|
|
OncLive
Dr. Santos on the FDA Approval of Ramucirumab/Erlotinib in EGFR-Mutant NSCLC
|
|
|
|
Edgardo S. Santos, MD, FACP, FCCP, a medical oncologist of internal medicine at Boca Raton Regional Hospital, discusses the FDA approval of the combination of ramucirumab (Cyramza) and erlotinib (Tarceva) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions or exon 21 substitution mutations.
The May 30, 2020 approval follows a 6 to 5 recommendation vote from the FDA's Oncologic Drugs Advisory Committee and is based on findings from the phase 3 RELAY trial.
Read more
|
|
|
|
|
|
|
|
|
OncLive
FDA Approves Ramucirumab Plus Erlotinib for Frontline EGFR+ NSCLC
|
|
|
|
At a median follow-up of 20.7 months, the investigator-assessed median progression-free survival (PFS) with the ramucirumab regimen versus erlotinib alone was 19.4 months (95% CI, 15.4-21.6) versus 12.4 months (95% CI, 11.0-13.5), respectively (HR, 0.59; 95% CI, 0.46-0.76; P <.0001).
The FDA has approved the combination of ramucirumab (Cyramza) and erlotinib (Tarceva) as a frontline treatment for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.
Read more
|
|
|
|
|
|
|
|
|
The ASCO Post
First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer - The ASCO Post
|
|
|
|
As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cell lung cancer (SCLC). The findings were simultaneously published in the Journal of Clinical Oncology.
In the double-blind trial, 453 patients were randomly assigned to receive pembrolizumab at 200 mg every 3 weeks (n = 228) or placebo (n = 225) for up to 35 cycles, plus 4 cycles of standard-dose etoposide/platinum, with platinum treatment consisting ...
Read more
|
|
|
|
|
|
|
|
|
Targeted Oncology
Patients With No Prior Therapy for Advanced Squamous NSCLC Respond to Tislelizumab Combo
|
|
|
|
Statistically significant improvement in progression-free survival (PFS) was seen with tislelizumab (BGB-A317) plus chemotherapy versus chemotherapy alone in Chinese patients with untreated advanced squamous non–small cell lung cancer (NSCLC), according to findings from the phase 3 BGB-A317-307 trial. These data were presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Program.1
The median PFS per Independent Review Committee (IRC) was 7.6 months when combining the anti–PD-1 agent tislelizumab with paclitaxel and carboplatin versus 5.5 months in the control arm of paclitaxel and carboplatin alone (HR, 0.524; 95% CI, 0.370-0.742; P = .0001).
Read more
|
|
|
|
|
|
|
|
|
OncLive
Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC
|
|
|
|
“The results from this phase 3 trial demonstrated that inhibiting the PD-1 pathway with tislelizumab, combined with standard chemotherapy, provided a clinically meaningful benefit to patients with advanced squamous NSCLC, as assessed by progression-free survival and response rates,” lead investigator Jie Wang, MD, PhD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, stated in a press release.“Lung cancer is the leading cause of cancer-related death in China, and with NSCLC comprising the most common form of the disease, it is critical to identify new treatments that address patient needs.”The multicenter, open-label, randomized, phase 3 BGB-A317-307 trial included 360 patients from...
Read more
|
|
|
|
|
|
|
|
|
MedScape
Third- and Further-line Therapy in Advanced NSCLC Patients
|
|
|
|
Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical characteristics and histological and biological features of the disease. In nonsquamous NSCLC, novel agents, such as pemetrexed and bevacizumab, have improved survival in the first-line setting. Maintenance therapy with pemetrexed and erlotinib resulted in improved progression-free survival compared with second-line therapy at disease progression.
Read more
|
|
|
|
|
|
|
|
|
Targeted Oncology
CASPIAN Update Shows Ongoing Survival Benefit With Durvalumab in ES-SCLC
|
|
|
|
Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program maintained the overall survival (OS) benefit of durvalumab (Imfinzi) treatment in combination with platinum etoposide chemotherapy in newly diagnosed patients with extensive-stage small cell lung cancer (ES-SCLC) after more than 2 years of follow-up.1
The findings solidify the use of the PD-L1 inhibitor in combination with etoposide plus either cisplatin or carboplatin (EP) as a new frontline standard of care for this patient population, principal investigator Luis Paz-Ares, MD, PhD, said in presenting the data.
After a median follow-up of 25.1 months, the median OS was 12.9 months (95% CI, 11.3-14.7) ...
Read more
|
|
|
|
|
|
|
|
|
OncLive
Frontline Durvalumab Maintains OS Benefit in Updated ES-SCLC Findings
|
|
|
|
The addition of durvalumab (Imfinzi) to standard chemotherapy continued to demonstrate an improvement in overall survival (OS) for patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), according to updated results from the phase 3 CASPIAN study presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.The findings solidify the use of the PD-L1 inhibitor in combination with etoposide plus either cisplatin or carboplatin (EP) as a new frontline standard of care for this patient population, principal investigator Luis Paz-Ares, MD, PhD, said in presenting the data.After a median follow-up of 25.1 months, the median OS was 12.9 months (95% CI, 11.3-14.7) among patients who received durvalum...
Read more
|
|
|
|
|
|
|
|
|
BioSpace
Manager, Medical Affairs Oncology job with Daiichi Sankyo | 2131488
|
|
|
|
Join a Legacy of Innovation 110 Years & Counting!
With over 100 years of scientific expertise & a presence in more than 20 countries, Daiichi Sankyo & its 15,000 employees around the world draw upon a rich legacy of innovation & a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension & thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research & development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart & kidney diseases, & ot...
Read more
|
|
|
|
|
|
|
|
|
Targeted Oncology
AMG 510 Demonstrates Early Promise in Advanced KRAS G12C-Mutant Solid Tumors
|
|
|
|
Early signals of anti-tumor activity and safety were demonstrated with the novel KRAS G12C inhibitor, AMG 510, in multiple advanced solid tumors that harbor KRAS G12C mutations, according to results presented at the 2020 ASCO Virtual Scientific Program.1
In a cohort of 25 patients treated with AMG 510 confirmed partial responses were observed in 3 patients who had appendiceal cancer, melanoma, and endometrial cancer, respectively. Thirteen patients achieved stable disease and included 6 patients with pancreatic cancer, 2 with appendiceal cancer, 1 with ampullary cancer, and 1 with bile duct cancer, 1 with endometrial cancer, 1 with sinonasal cancer, and 1 with unknown primary cancer.
The safety profile was consistent with previously rep...
Read more
|
|
|
|
|
|
|
|
|
OncLive
News Network On Location: ASCO 2020 Day 1
|
|
|
|
Browse by Series: All Inside Oncology Adjuvant Therapy for Early-Stage HER2-Positive Breast Cancer ASCO 2020 News Updates in HER2+ Metastatic Breast Cancer: HER2CLIMB Saturday Spotlight The State of Ovarian Cancer: How Ovarian Cancer Care is Evolving in the COVID-19 Pandemic Evolutions in Hepatocellular Carcinoma in the Era of COVID-19 Metastatic Triple Negative Breast Cancer: IMpassion130 A Treatment Option in Myelofibrosis CAR T-Cell Therapy During the COVID-19 Pandemic Oncology Nursing and the COVID-19 Pandemic Updates and Considerations for the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic The Impact of the COVID-19 Pandemic on Laboratory and Testing Approaches COVID-19 and Cancer Care: A Webinar Without Wa...
Read more
|
|
|
|
|
|
|
|
|
OncLive
AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors
|
|
|
|
AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer (NSCLC) and colorectal cancer (CRC), according to results presented at the 2020 ASCO Virtual Scientific Program.In a cohort of 25 patients treated with AMG 510 confirmed partial responses were observed in 3 patients who had appendiceal cancer, melanoma, and endometrial cancer, respectively.
Read more
|
|
|
|
|
|
|
|
|
Times of India
Vijender Kumar: Times of India Reporter
|
|
|
|
Haryana: Three agents booked for duping three deportees May 29, 2020Three Haryana travel agents have been booked by the police for duping three Jind residents by sending them to the United States illegally. Two of these deportees tested positive after they were sent back to India by the US on May 19.
May 28, 2020A 94-year-old man from Jind has shown that it is never too late to fulfil your dreams. He has spent Rs 52 lakh on the construction of a sub health centre on his land to provide health care to people of his area.
Read more
|
|
|
|
|
|
|
|
|
Times of India
Covid-19: Tamil Nadu plans to cap treatment cost as death toll reaches 160 | Chennai News - Times of India
|
|
|
|
Health workers take a swab test for coronavirus at primary health centre in Chennai. (File photo)
CHENNAI: Tamil Nadu moved to control pricing for Covid treatment and offer incentives for remaining in government quarantine on Saturday, which saw the state report the highest single-day rise of 938 positive cases, taking its tally to 21,184. Six people succumbed to the virus pushing the death toll to 160.
The medical expert committee recommended continuation of restrictions on public transport, places of worship and malls in Chennai, which logged 616 fresh cases.
Read more
|
|
|
|
|
|
|
|
|
Times of India
Now is the Time to Quit Tobacco and Choose Life - Times of India
|
|
|
|
This ‘World No Tobacco Day’ (WNTD), I am back again to make you all aware about the harmful effects of tobacco and encourage tobacco users to quit tobacco in all forms. This year theis “protecting youth from industry manipulation and preventing them from tobacco and nicotine use”. The facts and figures that follow are to alert you all and help you make an informed decision of choosing life over tobacco, especially in COVID times.More than 8 million people die due to tobacco related illnesses globally every year.
Read more
|
|
|
|
|
|
|
|
|
Times of India
‘Need to save youth from aggressive marketing by tobacco industry’ | Nagpur News - Times of India
|
|
|
|
Nagpur: World No Tobacco Day (WNTD) will be observed amid Covid-19 threat this year. TOI spoke to Dr Subrajit Dasgupta, who heads Central India ’s most prominent charity cancer hospital , Rashtra Sant Tukdoji Cancer Hospital in Nagpur, as director. Sharing world view of tobacco addiction, he stated that number of cigarette smokers and other tobacco product users is set to increase among low and middle-income groups during and post lockdown period. He underlined the need to counter the aggressive marketing by tobacco industry .
Read more
|
|
|
|
|
|
|
|
|
The Guardian
Silent witness: unseen Buster Keaton sketches underline his comic genius
|
|
|
|
Buster Keaton, king of the silent movie, death-defying stuntsman and one of Hollywood’s greatest comedians, was also a great believer in the art of improvisation. “As a rule, about 50% you have in your mind when you start the picture and the rest you develop as you’re making it,” he once told an interviewer.
Now, however, two previously unpublished sketches have come to light in which Keaton appears to undermine his commitment to making it up as he goes along, with jokes mapped out in minute and colourful detail.
Alek Lev, vice president of the International Buster Keaton Society, likened the papers to a “holy relic”, telling the Observer: “We have the honour of preserving laughs that Buster wrote for the world but didn’t get a chance to ...
Read more
|
|
|
|
|
|
|
|
|
Lung Cancer
AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation
|
|
|
|
In non–small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) may occur via bypass signals such as AXL or MET activation. We investigated the antitumor activity of CB469, a newly developed drug that targets both AXL and MET, in EGFR TKI-resistant NSCLC cells.
We generated EGFR TKI-resistant NSCLC cell lines with acquired resistance to erlotinib, gefitinib, and osimertinib (PC9/ER, HCC827/GR and HCC827/OR, respectively).
Read more
|
|
|
|
|
|
|
|
|
Springer
The novel long non-coding RNA LATS2-AS1-001 inhibits gastric cancer progression by regulating the LATS2/YAP1 signaling pathway via binding to EZH2
|
|
|
|
Abstract
To explore the expression pattern and role of the novel long non-coding RNA LATS2 antisense transcript 1 (LATS2-AS1-001) in gastric cancer (GC).
qRT-PCR was applied to evaluate LATS2-AS1-001 expression and correlation with LATS2 in GC. In vitro experiments were performed to investigate the role of LATS2-AS1-001 in GC cells. RNA immunoprecipitation (RIP) was performed to assess the interaction between EZH2 and LATS2-AS1-001. LATS2/YAP1 signaling pathway proteins were detected by immunoblot.
Read more
|
|
|
|
|
|
|
|
|
Springer
Afatinib/osimertinib
|
|
|
|
Lee P-H, et al. Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection. European Journal of Cancer 130: 272-274, May 2020. Available from: URL:
Read more
|
|
|
|
|
|
|
|
|
Springer
Afatinib/gefitinib/osimertinib
|
|
|
|
Xia H, et al. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clinical Lung Cancer 21: 247-254, No. 3, May 2020. Available from: URL:
Read more
|
|
|
|
|
|
|
|
|
Nature
Heading off cancer at the pass
|
|
|
|
Cancer remains the world’s second leading cause of death and the top killer in some high-income countries. Scientists at the Janssen Pharmaceutical Companies of Johnson & Johnson want to intercept cancerous tissue before it becomes a serious threat.
While there have been significant advances in treating advanced malignancy, even these new treatments fail to stop certain cancers after they grow and spread. The five-year survival rates for metastasized bladder and colorectal cancer, for example, are 5 and 15%, respectively.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
|
|
|
|
Absence of somatic mutations in plasma derived cell-free DNA found in liquid biopsy associated with improved survival
SINGAPORE, May 30, 2020 /PRNewswire/ -- According to the data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 29 May 2020, researchers at Samsung Medical Center in Seoul, Korea, have found useful prognostic information beyond actionable biomarkers when the Guardant360® test is performed on ALK-rearranged (ALK positive) non-small cell lung cancer (NSCLC) patients.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
The 50 best shows on Netflix right now
|
|
|
|
Netflix has a treasure trove of terrific movies that you can stream right now, but if you’re looking for more than just a two-hour commitment, it’s also got a boatload of great TV shows you can delve into to keep yourself occupied for days — or even weeks — on end. If you just finished a good series and need a new one to fill the void, Netflix is the place to go, given the service’s phenomenal mix of classic, current, and original programming. Below, we’ve rounded up the best shows on Netflix right now, so you can binge-watch without having to hunt for the right title.
Created By: Michael Dante DiMartino, Bryan Konietzko
Cast: Zach Tyler Eisen, Mako Iwamatsu, Mae Whitman
Number of Seasons: 3
Watch now
The Haunting of Hill House Netflix
Mo...
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Edited Transcript of BNTX.OQ earnings conference call or presentation 12-May-20 12:00pm GMT
|
|
|
|
May 30, 2020 (Thomson StreetEvents) -- Edited Transcript of BioNTech SE earnings conference call or presentation Tuesday, May 12, 2020 at 12:00:00pm GMT
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
H.C. Wainwright Co, LLC, Research Division - Associate
Thank you for standing by, and welcome to the BioNTech First Quarter 2020 Operational Progress and Financial Results Conference Call.
(Operator Instructions) I must advise you the conference is being recorded today, Tuesday, the 12th of May 2020.
I would now like to hand the call over to the Vice President, Investor Relations and Business Strategy, Sylke Maas.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Mersana Therapeutics, Inc. (MRSN) Stock Price, Quote, History & News - Yahoo Finance
|
|
|
|
Wall Street is experiencing some major déjà vu. The tensions between the U.S. and China flared after President Trump threatened to impose new import tariffs. The difference this time? These tariffs would serve as a punishment for China’s role in the COVID-19 pandemic. In response, stocks posted sharp declines, a rough start to the month of May.The new week of trading could see more of the same. U.S. stock pointed to losses in Monday's trading session as statements made by U.S. Secretary of State Mike Pompeo the day before failed to alleviate trade war fears.
Read more
|
|
|
|
|
|
|
|
|
Yahoo Finance
Blueprint Medicines Corporation (BPMC?P=BPMC) Stock Price, Quote, History & News - Yahoo Finance
|
|
|
|
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma.
Read more
|
|
|
|
|
|
|
|
|
Twitter
Gil Morgan NSCLC, LungCancer, EGFR, OncoAlert, LCSM: 31/05/2020 07:31:48
|
|
|
|
Just Out📣 @US_FDA 🇺🇸approves Ramucirumab injection💉in combo w/ Erlotinib for #NSCLC #LungCancer based on results from the RELAY trial. “Represents one step towards our goal of making #EGFR mutated🧬NSCLC in a manageable chronic disease” #OncoAlert #LCSM https://t.co/71YM3OLHhI
Read more
|
|
|
|
|
|
|
|
|
Twitter
Cancer Discovery EGFR, LungCancer, NSCLC: 30/05/2020 20:00:07
|
|
|
|
ICYMI: Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC
https://t.co/7V7Nq2Ajl6
Read more
|
|
|
|
|
|
|
|
|
Twitter
CellworksLife EGFR, NSCLC, DFS: 30/05/2020 16:30:28
|
|
|
|
Osimertinib Improves Disease-Free Survival in Patients with #EGFR-Mutated Advanced #NSCLC. #DFS
Read more
|
|
|
|
|
|
|
|
|
Twitter
Medicine Matters oncology ASCO20, osimertinib, LungCancer, NSCLC, LCSM: 30/05/2020 18:50:51
|
|
|
|
#ASCO20 news: ADAURA – Adjuvant #osimertinib “practice changing” for early-stage, EGFR-mutated non-small-cell #LungCancer, reported @DrRoyHerbstYale (@YaleCancer) #NSCLC #LCSM
Read more
|
|
|
|
|
|
|
|
|
Twitter
Jennifer Smith Osimertinib, NSCLC, ASCO20, ASCO2020, lcsm: 30/05/2020 20:35:36
|
|
|
|
#Osimertinib after complete resection is "practice-changing" for stage IB-IIIA EGFR-mutated #NSCLC, says @DrRoyHerbstYale. Data are from a press preview. Full data to be presented tomorrow as plenary abstract LBA5 https://t.co/Sb7ZQlN6Ji. #ASCO20 #ASCO2020 #lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
M-Luján Oncología ASCO20Colombia: 30/05/2020 17:15:55
|
|
|
|
#ASCO20Colombia Real-world data of a cohort of patients with EGFR mutated metastatic non-small cell lung cancer (NSCLC), follow up of 52 months in Fundación Santa Fe de Bogota. 👍🏻@Vanessa73815597 @docpino2 https://t.co/ZRb8aM2EXx
Read more
|
|
|
|
|
|
|
|
|
Twitter
The ASCO Post LCSM, oncology, cancer: 30/05/2020 17:30:39
|
|
|
|
.@US_FDA Approves First-Line Ramucirumab Plus Erlotinib for Metastatic EGFR-Mutated NSCLC
Read more
|
|
|
|
|
|
|
|
|
Twitter
Natasha Dhawan, MD ASCO20, LCSM: 30/05/2020 17:50:42
|
|
|
|
Molecular testing for NSCLC ⬆️ for EGFR/ALK but testing for additional targets still lacking.
⬆️ testing Recs:
1) Optimize communication with specialists to request enough tissue bx
2) Discuss w/ pathologist to ensure testing
3) Advocate for NGS test
#ASCO20 #LCSM @n8pennell
Read more
|
|
|
|
|
|
|
|
|
Twitter
IC-ONC Global Immunotherapy: 30/05/2020 18:56:02
|
|
|
|
"cytotoxic effector functions of lymphocytes (ie, through granzymes) critical for anti-PD-1 antibody-mediated immune effects" Granzyme B is correlated w/ clinical outcome after PD-1 blockade in pts w/ stage IV NSCLC https://t.co/8K7HajClPn #Immunotherapy
Read more
|
|
|
|
|
|
|
|
|
Twitter
JAMA Oncology bevacizumab, LCSM: 30/05/2020 19:00:00
|
|
|
|
Ph 2 study combining osimertinib w #bevacizumab as 1L treatment for EGFR mut’n-pos adv NSCLC meets efficacy threshold & reveals marked diff’s in outcomes depending on plasma clearance of circulating tumor DNA (ctDNA) 6 weeks from start of treatment
Read more
|
|
|
|
|
|
|
|
|
Twitter
Lisa Astor FDA: 30/05/2020 16:57:05
|
|
|
|
APPROVED! The #FDA has approved frontline ramucirumab plus erlotinib for the treatment of patients with metastatic NSCLC and EGFR exon 19 deletions or L858R mutations.
Read more
|
|
|
|
|
|
|
|
|
Twitter
Juan C Osorio MD : 30/05/2020 23:10:19
|
|
|
|
Antitumor Activity of an EGFR-cMet Bispecific Antibody in EGFR Exon 20 Insertion-Driven NSCLC. Both EGFR signaling inhibition and ADCC as mechanisms of action.
Read more
|
|
|
|
|
|
|
|
|
Twitter
Stephen Clendinnen TCM: 30/05/2020 23:27:14
|
|
|
|
"In this study, we identified the relationship between the YC or YH and the EGFR gene status, which may be the theoretical basis for further studies combining TCM therapies with EGFR-TKIs in NSCLC patients."
#TCM
Read more
|
|
|
|
|
|
|
|
|
Twitter
Bartomeu Massuti : 30/05/2020 23:32:48
|
|
|
|
Adjuvant Osimertinib Exceeds Expectations in EGFR-Positive NSCLC - The ASCO Post
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive SOSS lcsm: 31/05/2020 00:00:18
|
|
|
|
.@DCarboneMD, of @OSUCCC_James, sheds light on the importance of personalizing immunotherapy in NSCLC #lcsm
https://t.co/hwggRoXpVl
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive SOSS lcsm: 31/05/2020 02:00:07
|
|
|
|
Ronald B. Natale, MD, of @CedarsSinai, discusses the evolution of immunotherapy in advanced non–small cell lung cancer #lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
Janice Farias amivantamab, CETTROASCO20, lungcancer, asco20: 31/05/2020 02:44:28
|
|
|
|
💡 News for patients with EGFR Exon20ins mutated NSCLC: #amivantamab
Fully human EGFR-MET bispecific antibody.
ORR 36% for all; 41% post-platinum
▶️FDA Breakthrough Therapy Designation after platinum
@CettroOncologia #CETTROASCO20 #lungcancer #asco20
Read more
|
|
|
|
|
